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Extensive weight loss reveals 
distinct gene expression changes 
in human subcutaneous and 
visceral adipose tissue
Adil Mardinoglu1,2, John T. Heiker3, Daniel Gärtner4, Elias Björnson1, Michael R. Schön4, 
Gesine Flehmig3, Nora Klöting5, Knut Krohn6, Mathias Fasshauer3, Michael Stumvoll3, 
Jens Nielsen1,2 & Matthias Blüher3
Weight loss has been shown to significantly improve Adipose tissue (AT) function, however changes 
in AT gene expression profiles particularly in visceral AT (VAT) have not been systematically studied. 
Here, we tested the hypothesis that extensive weight loss in response to bariatric surgery (BS) 
causes AT gene expression changes, which may affect energy and lipid metabolism, inflammation 
and secretory function of AT. We assessed gene expression changes by whole genome expression 
chips in AT samples obtained from six morbidly obese individuals, who underwent a two step BS 
strategy with sleeve gastrectomy as initial and a Roux-en-Y gastric bypass as second step surgery 
after 12 ± 2 months. Global gene expression differences in VAT and subcutaneous (S)AT were 
analyzed through the use of genome-scale metabolic model (GEM) for adipocytes. Significantly 
altered gene expressions were PCR-validated in 16 individuals, which also underwent a two-step 
surgery intervention. We found increased expression of cell death-inducing DFFA-like effector a 
(CIDEA), involved in formation of lipid droplets in both fat depots in response to significant weight 
loss. We observed that expression of the genes associated with metabolic reactions involved in 
NAD+, glutathione and branched chain amino acid metabolism are significantly increased in AT 
depots after surgery-induced weight loss.
Obesity is a complex disorder with various contributing genetic, psychological and environmental factors 
and it is characterized by deposition of an excess amount of fat in the adipose tissue (AT). Obesity has 
become one of the most serious public health problems of the 21st century and its worldwide prevalence 
continues to rise not only in adults but also in children and adolescents. Globally, nearly 1.5 billion 
adults and 43 million preschool children are overweight (body mass index (BMI) > 25 kg/m2) or obese 
(BMI > 30 kg/m2)1,2. Epidemiologic studies have shown that obesity is associated with increased mortal-
ity and that it is a major risk factor in the progression of serious medical conditions including type 2 
diabetes (T2D), cardiovascular disease, non-alcoholic fatty liver disease (NAFLD) and certain cancers3.
Fat deposition in visceral depots makes obese individuals more prone to complications than sub-
cutaneous fat accumulation4. Adipocytes and other AT cells from subcutaneous (S) and visceral (V) 
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ATs release a plethora of bioactive molecules, metabolites, lipids, proteins and hormones (adipokines)5. 
Adipokines mediate the crosstalk of AT with major organs and tissues, and thus modulate whole-body 
metabolism, inflammatory and immune processes6. Even though a multidisciplinary research effort 
involving clinical, genetic, biochemical, pharmacological and omics approaches is engaged, the underly-
ing molecular mechanisms for the progression of obesity associated diseases in adipocytes have not been 
fully elucidated. On that note, the mechanisms underlying beneficial effects of significant weight loss on 
obesity related diseases and associated risk factors also remain unclear.
In multiple studies, weight loss has been shown to improve disease risk factors and prevent T2D devel-
opment in obese individuals7–9. However, significant weight loss is only achieved by intensive life-style 
intervention and maintaining long-term weight loss or at least preventing weight regain remain major 
challenges10,11. Furthermore, life-style interventions have not been proven to be effective in the long term 
clinical treatment of morbid obesity12. Previous retrospective cohort studies have shown that bariatric 
surgery (BS) is the most effective intervention to reduce body weight, obesity associated disease risk fac-
tors and overall mortality in morbidly obese individuals in the long term13–15. The use of BS has increased 
dramatically during the past decade due to an acceptable risk/benefit profile16. Considerable metabolic 
improvements are seen in morbidly obese individuals after BS and further mechanistic insights into the 
activated mechanisms in response to BS will potentially lead to non-invasive treatments for obesity17,18.
There are already cross-sectional data available for global gene expression profiling in SAT and VAT of 
obese individuals19–25. Moreover, proteins in adipocytes have been characterized and used for the recon-
struction of a GEnome-scale metabolic Model (GEM) for adipocytes, iAdipocytes180926. GEMs are the 
collection of the biochemical reactions and associated enzymes in a cell/tissue type and they provide an 
excellent scaffold for analyzing the complexity of metabolism26–31. These integrative models are employed 
for prediction of complex phenotypes from genotypes in health and disease states27,32–43. Recently, the 
content of iAdipocytes1809 has been validated through the use SAT RNA sequencing data and updated 
based on the latest proteomics data in Human Protein Atlas (www.proteinatlas.org)44–49 to reconstruct 
iAdipocytes185050. In this context, GEM for adipocytes has been used for the integration of omics data 
of healthy and obese individuals and for the analysis of the SAT transcriptomics data of lean and obese 
individuals involved in the Swedish Obese Subjects Sib Pair study26,50.
Here, we performed two-step BS with sleeve gastrectomy as first and a Roux-en-Y gastric bypass sur-
gery as second step in 22 severely obese individuals (Table 1). In order to increase our knowledge about 
the complexity of biological processes associated with BS, we obtained SAT and VAT samples from the 
same individuals at the two surgery time points, and performed global gene expression profile analyses of 
SAT and VAT for six of the severely obese individuals using microarrays. Using these data, we revealed 
the biological processes altered in SAT and VAT of the obese individuals in response to BS through inte-
grative analysis engaging iAdipocytes1850. We tested in an unbiased microarray approach the hypotheses 
that extensive weight loss affects the gene expression profiling of VAT and SAT, and causes alterations 
in pathways associated with AT energy and lipid metabolism, inflammation, and secretory function 
Characteristic Baseline 12 months post-surgery P-value
Body weight (kg) 152 ± 36.3 110 ± 21.1 5.6E-05
BMI (kg/m2) 53.1 ± 10.1 38.6 ± 6.69 3.2E-06
Fasting plasma glucose (FPG) (mmol/l) 6.87 ± 1.81 5.16 ± 0.71 4.0E-04
Fasting plasma insulin (FPI) (pmol/l) 191 ± 145 66.5 ± 46.1 9.6E-04
HbA1c (%) 6.23 ± 0.93 5.31 ± 0.50 3.6E-04
Triacylglycerol (TG) (mmol/l) 1.78 ± 0.56 1.10 ± 0.36 4.2E-05
Free fatty acids (FFA) (mmol/l) 0.93 ± 0.25 0.37 ± 0.20 5.1E-10
Total cholesterol (mmol/l) 4.97 ± 0.93 4.73 ± 0.74 0.34
LDL-cholesterol (mmol/l) 3.14 ± 0.67 2.97 ± 0.84 0.51
HDL-cholesterol (mmol/l) 1.04 ± 0.31 1.39 ± 0.28 4.8E-04
C-reactive protein (CrP) (mg/l) 6.11 ± 3.26 2.26 ± 1.39 2.9E-05
Alanine aminotransferase (μ kat/l) 0.83 ± 0.41 0.48 ± 0.25 1.8E-03
Aspartate transaminase (μ kat/l) 0.66 ± 0.33 0.39 ± 0.16 2.3E-03
γ -Glutamyl transferase (μ kat/l) 0.82 ± 0.63 0.41 ± 0.18 8.5E-03
Leptin (ng/ml) 57.9 ± 16.9 33.0 ± 10.6 1.8E-06
Adiponectin (μ g/ml) 4.88 ± 3.04 10.3 ± 2.25 9.1E-08
Table 1.  Clinical characteristic of the study participants. Data are shown as means ± SD. P-value 
indicates significance-level of difference before and after weight loss for the 22 individuals undergoing 
bariatric surgery.
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(e.g. adipokines). Finally, we validated a subset of our significant findings by quantitative reverse tran-
scription PCR (RT-PCR) methods using SAT and VAT samples obtained from 16 independent individ-
uals that underwent BS.
Results
Characteristics of study participants. In 22 severely obese individuals, we performed a two step 
bariatric surgery strategy (first step: sleeve gastrectomy; second step after 12 ± 2 months: Roux-en-Y gas-
tric bypass surgery). Anthropometric and circulating parameters of the participants are shown in Table 1 
and Supplementary Dataset 1 before and after the extensive weight loss. BS caused an average 42 kg of 
body weight and 14.5 BMI reduction in obese individuals involved in our study (Table 1). We collected 
SAT and VAT samples as previously described51 from these 22 individuals before and after weight loss, 
and generated microarray gene expression data for a subgroup of six representative individuals. The 
independent SAT and VAT samples from 16 individuals were used to validate significantly altered gene 
expression by RT-PCR. To identify a potential gender bias, we tested gene expression changes after signif-
icant weight loss validated by QRT-PCR separately for men and women and confirmed all gene expres-
sion changes independently of the gender. Moreover, we did not find any differences in the expression 
of the validated genes between men and women.
Several clinical variables significantly changed and indicated improved health status in these severely 
obese individuals (Table  1). Parameters related to insulin resistance and T2D including fasting plasma 
glucose (FPG), fasting plasma insulin (FPI) and hemoglobin A1c (HbA1c) were all significantly decreased 
indicating improved insulin sensitivity after weight loss. HDL cholesterol and circulating adiponectin 
significantly increased and fasting plasma triacylglycerol (TG) was significantly decreased and indicated 
improved blood lipid status. Hypertriglyceridemia was evident (fasting TG > 1.7 mmol/L) in 11 out of 
22 individual before the weight loss but only in one individual after the weight loss. C-reactive protein 
(CrP), leptin serum concentrations and liver function parameters alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT) and γ -Glutamyl transferase (gGT) were significantly decreased in 
response to weight loss (Table 1). Interestingly, LDL cholesterol and total cholesterol were both within 
the normal range at baseline and did not change during the study. Overall, the likely increase in insulin 
sensitivity, the large reduction in fasting triglycerides and the increase in HDL cholesterol strongly indi-
cated improved health status of the individuals in response to weight loss.
Global gene expression profiling of SAT and VAT. Gene expression profiling of AT depots was 
performed using Illumina HumanHT-12 V4.0 whole genome expression chip for six of the individuals 
involved in our study (Fig. 1A). Due to the heterogeneity of the BMI before (40.9 < BMI < 65 kg/m2) and 
after (26.7 < BMI < 54.6 kg/m2) extensive weight lost, we compared the expression level of genes in AT 
depots of obese individuals to healthy lean individuals (internal additional control) for hereby, identifying 
significantly differentially expressed genes before and after the extensive weight loss, and finally detected 
the direction of the changes in the expression of the genes (Fig. 1B). Differential expression analysis was 
Figure 1. Global gene expression profiling of VAT and SAT before and after extensive weight loss. 
(A) VAT and SAT samples were obtained from individuals who underwent two-step bariatric surgery and 
microarray data were generated. (B) Gene expression data for different adipose tissue depots was analyzed 
independently by comparing to the gene expression data of lean individuals. Differentially expressed probe 
sets, protein coding genes as well as the metabolic genes in iAdipocytes1850 were identified. (C) The overlap 
between the differentially expressed metabolic genes in iAdipocytes1850 in two different adipose tissue 
depots were shown and used in network dependent analysis.
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carried using the Piano R package52 and false discovery rate (FDR) adjusted p-values (Q-values) were cal-
culated. In total, 273 probe sets in the microarray chip were significantly (Q-values < 0.05) differentially 
expressed in SAT samples and 284 probe sets were significantly (Q-values < 0.05) differentially expressed 
in VAT samples comparing to the reference individuals. The complete list of the genes whose expression 
that changed in SAT and VAT after extensive weight loss is presented in Supplementary Dataset 2.
We carried out gene set analysis for Gene Ontology (GO) biological process (BP) terms to obtain a 
general perspective on the changes in SAT and VAT likely to result from the weight loss and calculated 
the gene set statistics using reporter algorithm implemented in the Piano R package52. We performed GO 
analysis by comparing global SAT and VAT gene expression of individuals before and after weight loss to 
the gene expressions of lean individuals and presented the significantly enriched GO BP terms for SAT 
and VAT before and after the weight loss (Figure S1–S4). We observed that GO BP terms associated with 
immune response, regulation of protein secretion and lipid metabolism particularly lipid storage, nega-
tive regulation of lipid catabolic process and low-density lipoprotein particle clearance were significantly 
enriched after the extensive weight loss.
In SAT, expression of genes including integrin, beta 2 (ITGB2), lipopolysaccharide binding protein 
(LBP), lymphocyte cytosolic protein 1 (LCP1), matrix metallopeptidase 9 (MMP9), secreted phosphop-
rotein 1 (SPP1) and Thy-1 cell surface antigen (THY1) associated with the GO Term “immune sys-
tem process” were significantly decreased after extensive weight loss. Moreover, in VAT, expression of 
aquaporin 9 (AQP9), complement factor B (CFB), interferon regulatory factor 1 (IRF1), proteoglycan 
4 (PRG4) and metalloproteinase inhibitor 1 (TIMP1) associated with the GO Term “immune system 
process” were significantly decreased after extensive weight loss. This indicated the decreased immune 
response of the AT depots after weight loss.
Differences in SAT and VAT lipid metabolism in response to BS. In order to get a general over-
view about the expression changes of metabolic genes (genes in iAdipocytes1850) in SAT and VAT in 
response to weight loss, detailed metabolic differences were identified by mapping the significantly differ-
entially expressed genes on the network topology provided by iAdipocytes1850 (Figure S5). We identified 
lipid metabolism particularly the formation of lipid droplet (LD) in both SAT and VAT as most strongly 
affected metabolic pathway in response to extensive weight loss (Fig. 2). Through network analysis, we 
found that expression of cell death-inducing DFFA-like effector a (CIDEA) as well as lipin 1 (LPIN1), 
Figure 2. Increased formation of lipid droplet in VAT and SAT of obese individuals after extensive 
weight loss. Even though limited number of metabolic genes was differentially expressed in both adipose 
tissue depots, the expression of several genes involved in the formation of lipid droplets was increased. Red 
and dark red arrows indicated the significant upregulation of the associated genes in SAT only (light red) 
and in both SAT and VAT (dark red), respectively.
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abhydrolase domain containing 5 (ABHD5), 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9), 
aldolase C, fructose-bisphosphate (ALDOC) involved in the formation of LDs were increased in SAT 
and VAT of obese individuals after weight loss. Moreover, we found that the expression of diacylglycerol 
O-acyltransferase 2 (DGAT2), choline/ethanolamine phosphotransferase 1 (CEPT1), CD36 molecule 
(CD36), low density lipoprotein receptor (LDLR) and stearoyl-CoA desaturase 5 (SCD) involved in the 
lipid metabolism are increased in SAT after weight loss (Supplementary Dataset 2). We analyzed the 
expression levels of CIDEA and LPIN1 in the SAT and VAT samples obtained from an independent 
cohort of 16 obese individuals by quantitative RT-PCR and found that expression of these two genes 
were significantly (Student’s t test, P-value < 0.05) increased after BS (Fig. 3).
Moreover, we found that the expression of lipolytic genes including hormone-sensitive lipase, LIPE 
(HSL) and patatin-like phospholipase domain-containing protein 2, PNPLA2 (ATGL) were significantly 
altered by extensive weight loss (p < 0.05). However, after multiple testing the calculated Q-value was 
higher than 0.05 which we used as a cut of for detecting the statistically significantly changed genes in 
our study.
Increased expression of the genes catalyzing glutathione and NAD+ related reactions. We 
observed that the expression of glutathione s-transferase theta 1 (GSTT1) gene associated with reactions 
that use glutathione as cofactor is increased in both SAT and VAT after weight loss (Fig. 2). Glutathione 
can be synthesized from amino acids glutamate, cysteine and glycine through de novo glutathione syn-
thesis pathways. It is a key metabolite for the reduction of the damage to cellular components caused by 
reactive oxygen species (ROS), such as H2O2. In order to perform this vital function, cells need to main-
tain a pool of glutathione in the reduced state (GSH) and this requires an increased pool of glutathione 
through de novo biosynthesis.
Weight loss may lead to a significant increase in glutathione levels since genes catalyzing reactions 
that use glutathione as substrate were significantly (Q-values < 0.05) upregulated. We first checked 
the expression of enzymes involved in glutathione synthesis by RT-QPCR and observed that none of 
these enzymes (GCLC, GCLM and GSS) were significantly different in SAT and VAT after weight loss. 
Glutathione may also be regenerated from its oxidized form, GSSG by glutathione reductase (GR) that 
requires NADPH as a substrate. The resulting NADPH is directly linked to GSH synthesis. Hence, we 
measured the expression of Nicotinamide nucleotide transhydrogenase (NNT) that catalyzes mitochon-
drial transmembrane hydride transfer between NADH and NADP+ to generate NADPH in SAT and 
VAT of the individuals before and after the weight loss by RT-QPCR. We found that expression of the 
NNT is significantly (Student’s t test, P-value  < 0.05) increased in the SAT and VAT after extensive 
weight loss (Fig. 3). Taken together, these observations indicate that individuals who underwent BS may 
have higher total glutathione levels and these could be explained by the increased expression of NNT 
in AT depots.
In addition, expression of nicotinamide nucleotide adenylyltransferase 2, NMNAT2 involved in the 
NAD+ salvage pathways in SAT as well as changes in the expression NAD+ consuming enzymes in 
SAT and VAT increased after weight loss (Figure S5). Intracellular levels of NAD+ play a major role in 
maintaining the regular metabolic status of the cell and the total NAD+ pool within the cell is stabilized 
between de novo and salvage biosynthetic pathways and its utilization. It has been earlier reported that 
Figure 3. Validation of the gene expression changes before and after extensive weight loss. The 
expression levels of CIDEA and LPIN1 involved in the formation of lipid droplets, BCAT1 and BCAT2 
involved in the catabolism of the branch chain amino acids, NMNAT2 involved in the NAD+ salvage 
pathway, NNT involved in the glutathione synthesis and MCP1 and MCP2 involved in the transport of 
pyruvate to the mitochondria before and after extensive weight loss were calculated by quantitative RT-PCR. 
Each bar represents the results from before and after extensive weight loss for 16 SAT and VAT samples, and 
mean ± standard error of the mean (SEM) values are presented. *Student’s t test was used and P-value < 0.05 
was considered statistically significant.
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the main sources of NAD+ within the cell are the salvage pathways53 and these require uptake of NAD+ 
precursors including nicotinamide D-ribonucleotide and nicotinamide ribonucleoside from outside of 
the cells. We confirmed increased expression of NMNAT2 in SAT by RT-PCR (Fig.  3). On the other 
hand, we could not detect any significant changes in the expression of NMNAT2 in VAT of obese indi-
viduals after weight loss based on microarray and RT-PCR data.
Previously, it has been shown that AT is the major source of the elevated plasma ROS in obese mice 
when other tissues including the liver, skeletal muscle, and aorta are examined54. We observed that the 
expression of genes (NMNAT2) involved in the synthesis of NAD+ was increased selectively in SAT 
after extensive weight loss.
Increased expression of genes associated with the mitochondrial energy metabolism. 
Mitochondrial dysfunction due to impaired oxidative phosphorylation is a well-established consequence 
of obesity. Intracellular levels of NAD+ play a key role in the homeostatic control of mitochondrial 
function of the cell. We hypothesized that increased levels of NAD+ after extensive weight loss could 
also boost the mitochondrial activity in both fat depots of obese individuals.
Previously, we have reported that the expression of the mitochondrial pyruvate carrier 1 (MPC1) and 
2 (MPC2) that are essential for several major pathways of carbohydrate, fat, and amino acid metabo-
lism55 are decreased in obesity50. In order to confirm the increased expression of the genes in the mito-
chondria after weight loss, we analyzed the expression of MPC1 and MPC2 using quantitative RT-PCR. 
We found that the expression of the MPC1 and MPC2 were significantly increased in SAT (Student’s 
t test, P-value  < 0.05) whereas the expression of MPC1 was significantly increased (Student’s t test, 
P-value < 0.05) in VAT after weight loss (Fig.  3). Increased expression of MPC1 and MPC2 in obese 
individuals after weight loss may indicate the increased mitochondrial activity in SAT and VAT of obese 
individuals having weight loss (Fig. 4). Moreover, we found that the expression of phosphoenolpyruvate 
Figure 4. Increased expression of the genes associated with the mitochondrial metabolic activity in 
SAT and VAT after extensive weight loss. Model for the expression of the genes involved in the transport 
of pyruvate from cytosol to mitochondria as well as the expression of the genes involved in the catabolism 
of branch chain amino acids in mitochondria is increased after extensive weight loss. Changes in gene 
expression before and after the extensive weight loss are highlighted in either red (higher expression) or blue 
(lower expression).
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carboxykinase 2 (PCK2), hydroxyacyl-CoA dehydrogenase (HADH) and aldehyde dehydrogenase 6 fam-
ily, member A1 (ALDH6A1) are increased in the SAT mitochondria after weight loss.
Alterations in the branched-chain amino acids metabolism. The branched-chain amino acids 
(BCAAs), leucine, isoleucine, and valine, are essential amino acids and it has been earlier reported that 
levels of BCAAs are elevated in plasma of obese individuals56. We found that expression of the ALDH6A1 
involved in the catabolism of the BCAA is significantly increased in SAT after BS. We have previously 
shown that plasma levels of BCAAs are increased due to decreased catabolism of BCAAs in SAT of obese 
individuals50. The catabolism of BCAA starts with transamination of BCAAs to α -keto acids (BCKAs) by 
cytosolic and mitochondrial branched-chain aminotransferases, BCAT1 and BCAT2, respectively. BCKAs 
can be released into the circulation, and liver can decarboxylate BCKAs to acyl coenzyme A (acyl-CoA) 
derivatives by the rate-limiting enzyme, branched-chain a-ketoacid dehydrogenase (BCKDH). We have 
previously reported that expression of BCAT1 is increased whereas the expression of BCAT2 is decreased 
in the SAT of obese individuals compared to lean individuals50.
We hypothesized that increased mitochondrial activity of both AT depots after BS, may result in 
increased catabolism of BCAAs. Hence, we compared the expression of BCAT2 in SAT and VAT of 
obese individuals before and after weight loss by quantitative RT-PCR analysis (Fig. 3) and found that 
expression of BCAT2 is increased in both SAT and VAT after BS (Fig. 4). Moreover, we found that the 
expression of BCAT1 is decreased in SAT after weight loss. On the other hand we could not detect 
significant changes in the expression of BCAT1 in VAT of obese individuals after extensive weight loss.
Discussion
AT stores and mobilizes triglycerides and has a major role in regulating whole-body metabolism. Using 
whole genome expression arrays, we determined SAT and VAT global gene expression changes in six 
obese individuals undergoing a two-step BS strategy causing extensive weight loss after sleeve gastrec-
tomy (first step surgery). Gene expression profiling of both SAT and VAT in the same individual after 
significant weight loss allowed us to delineate biological processes most likely related to weight loss. 
We observed that significant weight loss is associated with significant changes in blood pressure, TGs, 
HDL-cholesterol, CrP, adiponectin, FPG and FPI. These multiple significant changes in glucose and lipid 
metabolism as well as AT function in response to weight loss are significant confounding factors, which 
may either in a concerted mode or as single factors confound the observed gene expression changes. Our 
study design does therefore not allow drawing conclusions with regard to the specific causative factors 
of gene expression changes.
LDs are an important subcellular organelle that are found in adipocytes and have fundamental roles 
in metabolism. LDs protect the cell against lipotoxicity by sequestering excess fat and have roles in the 
development of obesity, T2D and NAFLD. We found that expressions of the SAT enriched gene CIDEA 
as well as other genes involved in the formation of LDs are increased after extensive weight loss. CIDEA 
is highly enriched in human SAT compared to other major 32 human tissues in healthy individuals50 
and it regulates the TG deposition in AT. It has been reported that the expression of CIDEA in VAT of 
obese individuals correlates positively with whole-body insulin sensitivity similar to the known LD pro-
tein perilipin57. LPIN1 is also highly expressed in human SAT50 and its expression positively correlated 
with insulin sensitivity whereas it inversely correlated with parameters of adiposity58. We have previously 
found that the expression of the CIDEA and LPIN1 is significantly downregulated in the SAT of male 
and female obese individuals compared to lean individuals50 and the expression of both genes were 
increased after extensive weight loss in morbidly obese subjects.
Cidea inhibits the brown adipose tissue uncoupling process in rodents and Cidea-null mice are lean 
and resistant to diet-induced obesity59. The association between CIDEA and basal metabolic have also 
been elucidated in human obesity and it has been found that its expression is inversely associated with 
basal metabolic rate and uncoupling protein 1 (UCP1) expression60. Decreased expression of CIDEA has 
been linked to high body fat content and high insulin levels in obese subjects. In addition to its role in 
lipid metabolism, Cidea has been found as a novel target gene for both peroxisome proliferator-activated 
receptor (PPAR)α and -γ in the mouse liver and the induction of Cidea in liver with PPARα and -γ 
agonists has suggested a possible role for Cidea in energy metabolism61.
The expression of CIDEA was also increased in cancer cachexia, a condition associated with extensive 
weight loss62. It has also been shown that the expression of BCAT2 changes in response to cachexia63 
and we found that expression of BCAT2 also changed in SAT and VAT of the individuals after extensive 
weight loss. There is a direct link to cachexia via CIDEA, as studies suggest that basal lipolysis is further 
decreased in human fat cells in cancer cachexia and this might be due to enhanced AT levels of CIDEA 
which decrease basal lipolysis in human AT. Cancer cachexia patients suffer from serious weight loss, 
primarily AT mass. Cachexia associated gene expression changes in AT mainly involve an upregulation 
of energy turnover regulating pathways, whereas genes controlling intra- and extracellular architecture 
were downregulated63. Similar changes have been found as a result of weight-loss in obese individuals64,65. 
Obesity, opposite to cachexia is associated with a state of chronic inflammation, but inflammatory genes 
were not found affected by SAT gene expression changes observed in cachexia66. In contrast, weight-loss 
is associated with significant downregulation of inflammatory pathways in the AT stromal vascular 
fraction67. Based on these findings, one might speculate that rapid and significant weight loss after BS 
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results in changes in AT gene expression profile towards a cachexia-associated pattern accompanied by 
improved metabolic and disease risk factors via additional changes in inflammatory gene expression.
Alterations in immune pathways were found in obese individuals and the level of inflammation was 
significantly decreased after extensive weight loss. We found that the expression of genes associated with 
immune processes were significantly decreased in both SAT and VAT. On the other hand, we detected 
significant differences in the plasma level of adiponectin and leptin, before and after weight loss but could 
not detected any significant changes in the expression of these genes in SAT and VAT of the individuals 
before and after weight loss.
The expected changes in the expression of lipolytic genes after the extensive weight loss were also 
detected in our analysis. However, after multiple testing the calculated Q-value was higher than 0.05 
which is used as a cut of for detecting the statistically significantly changed genes in our study. One 
plausible explanation can be the small sample size used in our study. In addition, we cannot exclude that 
a body weight maintenance phase two months prior to the 2nd step Roux-en-Y surgery may have caused 
the absence of expected gene expression changes in lipolytic genes. Another limitation of our study is 
that due to the relatively small sample size, a paired sample analysis could not be performed. Therefore 
further studies are required to confirm our results using larger cohorts and/or different methods (e.g. 
RNA sequencing) for the quantification of gene expression changes after significant weight loss.
In order to address obesity in a wider population of affected individuals, less invasive treatments than 
BS are needed. Our results can be used for understanding the underlying molecular mechanisms of the 
clinical and physiological effects of BS and designing less invasive and potentially safer interventions to 
mimic the effects of BS. In summary, we identified previously unrecognized gene expression changes 
in AT in response to extensive weight loss, which may represent targets for the future development of 
pharmacological weight loss treatments.
Materials and Methods
Study-subject characteristics. From 22 Caucasian obese volunteers (17 females and 5 males), plasma 
samples, SAT and VAT biopsies were obtained in the context of a two-step bariatric surgery strategy with 
gastric sleeve resection as the first step and a Roux-en-Y- gastric bypass as second step surgery 12 ± 2 
months after sleeve gastrectomy. The baseline BMI in this subgroup was 53.1 ± 10.3 kg/m2 and the BMI 
after gastric sleeve resection was 38.6 ± 6.8 kg/m2 (Table 1).
SAT and VAT samples obtained from six individuals (the first six women who completed the 2nd step 
surgery and in which AT RNA quality (tested by Agilent RNA 6000 Nano Kit, Agilent Technologies, 
Santa Clara, CA, USA) was sufficient for microarray experiments) at both surgery time points were 
used for microarray experiments and additional SAT and VAT samples obtained from 16 individu-
als (recruited subsequently after the first 6 individuals) were used to validate gene expression changes 
detected by microarray by RT-QPCR (Table 1). All study participants had a stable weight with no fluc-
tuations of more than 2% of the body weight for at least three months before surgery. Individuals with 
severe conditions including generalized inflammation or end stage malignant diseases were excluded 
from the study. VAT samples were obtained from the upper left part of the omentum. VAT and SAT sam-
ples were immediately frozen in liquid nitrogen after explanation. The study was approved by the Ethics 
Committee of the University of Leipzig (Reg. number: 017-12-23012012). The methods were carried out 
in accordance with approved guidelines and regulations. All participants gave written informed consent 
before taking part in the study.
Global transcriptome profiling of SAT and VAT. Total RNA was extracted as previously described68 
and SAT and VAT gene expressions were measured using Illumina HumanHT-12 V4.0 whole genome 
expression chip (Illumina Inc, San Diego, USA). Pre-processing of the raw data was done using Illumina 
software, GenomeStudio (Illumina Inc., San Diego). Chip background effects were corrected and the 
average bead signal and detection p-values were calculated using negative controls present on the array. 
Original raw data includes expression levels with chip background levels subtracted and detection 
p-values for over 47,000 probes.
The output of the GenomeStudio was uploaded to the MATLAB and the quantilenorm function was 
used to apply quantile normalization. SAT and VAT samples processed separately and probes which did 
not have detection p-value < 0.05 in any of the samples were removed. The “genelowvalfilter” function 
was used to filter out genes with very low absolute expression and “genevarfilter” function to filter out 
genes with a small variance across samples were applied to the normalized data. 25,696 and 25,897 
probes were retained for SAT and VAT samples respectively.
Due to the difference between the size of the adipocytes in the SAT and VAT samples, the microarray 
data were in addition normalized to AT depot specific reference genes. The use of the reference genes 
depends on the tissue type and the experimental conditions. Throughout our analysis, the β -glucuronidase 
(GUSB) gene and β -Actin (ACTB) were used as reference in SAT and VAT, respectively. GUSB was 
reported as the best reference gene in SAT due to its steady mRNA level at different body weights and 
fat mass across the replicate samples69. Similarly, ACTB was suggested as a reference gene in the gene 
expression studies of the human VAT samples70.
We compared gene expression profiles in SAT and VAT of severe obese individuals with that of lean 
individuals. In parallel, a Singular Value Decomposition (SVD) and a standard clustering analysis were 
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employed to identify gross patterns of the transcriptome. P-values were corrected for multiple testing 
and analysis of variance (ANOVA) was used to determine significance of differences between ratios at 
Q-values < 0.05 and log2 fold changes > 0.1.
RT-PCR. SAT and VAT samples were immediately frozen in liquid nitrogen after explanation. Total 
RNA was extracted from frozen SAT and VAT obtained from 16 obese male and female individu-
als underwent BS before and after the surgery using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, 
Germany). Assay-on-demand (ABI, Foster City, USA) probes were used for the quantitative RT-PCR, 
performed in a 96-well LightCycler 480 system. Expression levels of CIDEA, LPIN1, NMNAT2, MPC1, 
MPC2, NNT, BCAT1 and BCAT2 were calculated relative to the mRNA expression of GUSB in SAT and 
ACTB in VAT and calculated with the Δ Δ -Ct method.
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